Intracellular ROS-scavenging nanozymes for the treatment of osteoarthritis

Jessica L. Aldrich¹, Gengfu Dong¹, Arjun Panicker¹, Tomas Gayoso¹, Jennifer Russell¹, Kyle D. Allen¹, Terence Ryan¹, Blanka Sharma¹
¹University of Florida, Gainesville, FL

Disclosures: Jessica Aldrich (N), Gengfu Dong (N), Arjun Panicker (N), Tomas Gayoso (N), Jennifer Russell (N), Kyle Allen (editor - OAC), Terence Ryan (N), Blanka Sharma (42Bio).

INTRODUCTION: Nanozymes, antioxidant-mimicking nanoscale biomaterials, are an emerging therapeutic strategy in medical applications related to oxidative stress. These nanomaterials can be engineered to mimic endogenous enzymes, such as catalase or superoxide dismutase, or can directly scavenge excess reactive oxygen species (ROS) that contribute to the progression of oxidative stress. Oxidative stress plays a central role in the development of osteoarthritis, however it remains an elusive therapeutic target – conventional small molecule antioxidants and natural enzymes have been limited by poor retention and localisation to the osteoarthritic (OA) joint. In contrast, nanozymes can be engineered with properties that confer better stability and bioavailability than existing antioxidant therapies¹. One example includes manganese dioxide nanoparticles (MnO₂ NPs), which our group has engineered with properties favorable for cartilage localisation and chondrocyte uptake, and consequently chondroprotection upon oxidative stress induction¹. However, there is little understanding of the molecular mechanisms and compartment specific functions of MnO₂, or other nanozymes currently evaluated as potential OA therapies. The objective of this work was to evaluate the uptake mechanisms and intracellular localization of MnO₂ NPs in human OA chondrocytes and determine the compartment specific ROS scavenging activity of MnO₂ NPs.

METHODS: MnO₂ NPs were synthesized with cartilage targeting properties (cationic, <15 mm) following previously reported methods². Human OA chondrocytes were isolated from patients undergoing total knee arthroplasty (n = 3 male and n = 3 female). Passive and active methods of NP uptake into human OA chondrocytes were determined via temperature dependent uptake studies (37°C and 4°C) at 5 and 20 ug/ml MnO₂. Intracellular localization of MnO₂ NPs was determined via confocal microscopy for colocalization with MitoTracker and LysoTracker fluorescent tags. To evaluate ROS scavenging activity and location, bovine chondrocytes were transfected with plasmids encoding HyPer7, an ultraviolet genetically encoded hydrogen peroxide (H₂O₂) sensor, treated with MnO₂ NPs (5 ug/ml and 20 ug/ml), and then washed and exposed to increasing levels of H₂O₂ over time³. Oxidation of the probe by H₂O₂ results in a shift in its excitation wavelength - the readout of HyPer7 is thus presented as ratio of fluorescence emission intensity a following excitation at the 2 respective wavelengths (488 and 405nm). HyPer7 plasmids contained localization signals targeting either the mitochondrial matrix, mitochondrial intermembrane space, or cytosol, were used to determine compartment specific H₂O₂ scavenging ability of the MnO₂ NPs. Statistical analysis was conducted on GraphPad PRISM 10.2 whereby error bars indicate standard deviations and statistical comparison of means were conducted in GraphPad via a Dunnnett’s test or one-way ANOVA with Tukey’s multiple comparisons tests.

RESULTS: MnO₂ NPs were visualized within human and bovine chondrocytes. Uptake was dose dependent, with increasing mean fluorescent intensity from 5 to 20 ug/ml, without impacting viability. While uptake was greater at 37°C compared with 4°C, there was measurable uptake at both temperatures, suggesting that MnO₂ utilized both active and passive routes of uptake (Fig 1A). There is no significant difference in MnO₂ NP uptake between male and female donors, based on mean fluorescent intensity. Intracellularly, MnO₂ colocalized to mitochondria and lysosomes, indicated by 0.6 and 0.4 Pearson correlation coefficients, respectively (Fig 1B). Results from the HyPer7 probes (Hyper 7 ratio) showed that MnO₂ NPs reduced H₂O₂ levels in all three cellular compartments evaluated, with dose dependence noted in the mitochondrial matrix and intermembrane space. The thiol reducing agent dithiothreitol (DTT), was used to reverse the HyPer7 oxidation, acting as a positive control to confirm cell response returns to baseline.

DISCUSSION: MnO₂ NPs have a unique ability to enter chondrocytes and scavenge ROS in multiple cellular compartments. MnO₂ NPs enter chondrocytes through both passive and active transport mechanisms, rendering them available for localization to the cytosol and mitochondria. Colocalization and function of MnO₂ within the mitochondria may be driven by the electrostatic interaction between the cationic MnO₂ and the negatively charged mitochondrial matrix. Mitochondria are responsible for generating a significant amount of ROS within the cell and colocalization of MnO₂ may support endogenous antioxidant function, such as MnSOD (superoxide dismutase), or directly scavenging H₂O₂ produced by the mitochondria. This is the first mechanistic analysis of the redox activity of MnO₂ NPs in chondrocytes. The limited molecular tools to measure ROS has impeded the progress in antioxidant therapies. The HyPer7 probes have been introduced into the field 17 years ago and have been used with other cell types, but this is the first instance of their use in chondrocytes, further expanding their application potential. MnO₂ scavenging is dose dependent, with a lower HyPer7 ratio in cells treated with 20 ug/ml MnO₂ before the addition of exogenous H₂O₂ in all compartments except for the cytosol. This may suggest a saturation effect of MnO₂ on H₂O₂ in the cytosol. Comparatively, scavenging H₂O₂ in the mitochondria may support overall cellular function and redox homeostasis, as suggested in our previous reports of the downstream effects of MnO₂ NPs. Advancing our understanding of how these nanomaterials deliver a therapeutic response is important for continuing to find treatments for stopping or slowing OA progression.

SIGNIFICANCE/CLINICAL RELEVANCE: Nanozymes such as MnO₂ are emerging technologies for effectively targeting oxidative in the treatment of numerous diseases including OA. This study is the first to interrogate the uptake and ROS scavenging mechanisms of MnO₂ NPs in chondrocytes, which will be important for further development and translation of this promising therapeutic strategy.

ACKNOWLEDGEMENTS: This material is based upon work supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01AR071335, R01AR080687: and F31AR083291.


ORS 2024 Annual Meeting Paper No. 280